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 PROFFERED PAPERS: CLINICAL 3:  
PARTIAL BREAST IRRADIATION (RANDOMISED trials)  
  
OC-0234   
Intraoperative partial breast irradiation: The ELIOT trial results at 
5-years  
R. Orecchia1 
1European Institute of Oncology, Radiation Oncology, Milan, Italy  
 
Purpose/Objective: Electron Intra Operative Radiation Therapy has 
been extensively tested in Milan since 1999. After a pilot trial on 101 
patients in order to identify the maximum tolerated dose, a 
randomized study, named ELIOT,has been carried out from 2000 to 
2007. Aims of the study was to compare patients submitted to a 21 Gy 
single-fraction treatment targeted at the tumour bed only, given at 
the time of the quadrantectomy, versus standard post-operative WBI 
after the same BCS. 
Materials and Methods: We didn’t select specific subgroups of 
patients theoretically at higher or lower risk. Eligible patients were 
women with early invasive ductal or lobular breast cancer with a 
maximum diameter up to 25 mm if they were aged between 48 and 75 
years old and suitable for BCS. The study protocol was approved by 
the institutional ethical committee and a written informed consent 
was obtained from eligible patients before assignment to treatment. 
The primary endpoint was the incidence of local relapse, including 
ipsilateral breast cancer. Based on literature data available at the 
time of the study design (July 2000) and our previous experience, the 
expected 5-years rate in the conventional arm was about 3%. Tobe 
equivalent the observed rate should be kept under the 7.5% in the 
ELIOT arm. Secondary endpoints included overall survival, incidence 
of axillary or distant metastasis, contralateral breast cancer, and 
other primary cancers. 
Results: A total of 1305 breast cancer patients were randomized 
before surgery in the study (654 in the WBI arm and 651 in the ELIOT 
arm). Due to ineligibility, 119 patients were excluded and a total of 
1186 patients were available for analysis (601 in the WBI arm and 585 
in the ELIOT arm). The analysis is based on effective treatment 
received and not an intention-to-treat. The two treatment groups 
were perfectly comparable at baseline, with only tumor grade 
differentially distributed with a higher frequency of G1 tumor in the 
ELIOT arm (p=0.03). All the events are reported at the 5-year follow-
up. An excess of “true local relapses” (WBI = 5/ ELIOT = 23), 
“ipsilateral breast cancer”(0/14, respectively) and “axillary/regional 
lymphonode metastases” (2/9, respectively) in the ELIOT group were 
observed. An excess of controlateral breast cancer, but without 
significant statistical difference, was observed in the conventional 
arm, 1.7% versus 0.8%. If we consider the cumulative incidence of new 
cancers not related to the recurrence in index quadrant (ipsilateral 
and contralateral second cancer) we observed a rate of 1.7 in the WBI 
arm, and 2.9in the ELIOT arm.  We found a low rate of local relapse in 
women with small tumor (≤1cm), grade 1 tumor and luminal A tumor. 
Among 200 patients with small (≤1cm) luminal A breast cancer we 
observed only one local relapse in the WBI group versus 2 in the ELIOT 
group (log-rank p=0.55). Among 986 patients with either large (>1cm) 
or non luminal A breast cancer we observed 4 local relapses in the WBI 
group versus 35 in the ELIOT group (log-rank p<0.0001). In order to 
assess some subgroups of patients to be selected for ELIOT treatment 
without statistical differences with the conventional arm, we 
stratified the patients according to the ASTRO criteria. We had 129 
patients in the “suitable” group,270 in the “cautionary”, and 184 in 
the “unsuitable group. In the low risk group no statistical differences 
have been observed between the two arms. No differences were 
observed in death rate and overall survival. The actuarial10-year 
overall survival rates were 92.0 and 89.8, respectively (P=0.69). 
Conclusions: This study contributes to identify properly selected 
patients for PBI. New issues of biology-oriented patient selection need 
to be validated with independent data sets and new generation of 
randomized trials. 
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Purpose/Objective: To compare 1-year toxicities of accelerated 
partial breast irradiation (APBI) with multicatheter brachytherapy (BT) 
to whole breast irradiation (WBI) in a low-risk group of breast 
carcinoma. 
Materials and Methods: Between May 2004 and July 2009, 1195 
eligible patients with Stage 0/I/II (pTis-1-2 pN0-1mi M0) breast cancer 
were prospectively enrolled on the protocol. Patients allocated to the 
standard arm received 50 Gy WBI followed by a tumor bed boost of 10 
Gy. Patients in the experimental arm were treated with APBI using 
multicatheter BT up to 32.0 Gy/8 fractions or 30.3 Gy/7 fractions 
(HDR-BT) or up to 50 Gy/0.60-0.80 Gy (1 pulse/hour, 24 hours/day; 
PDR-BT). We report early side-effects and 1-year toxicities of 1193 
patients, who were treated according to study protocol (WBI: n=560 
vs. APBI: n=633). Side effects were documented according to the CTC-
AE v3 and the RTOG/EORTC late radiation morbidity scoring schemes. 
The cosmetic outcome was judged by digital photographs. This study 
is registered at ClinicalTrials.gov: NCT00402519.  
Results: Both WBI and APBI were well tolerated with moderate early 
side-effects at the end of therapy: acute dermatitis (Grade 1: 49.5% 
vs. 18.2%, Grade 2: 35.7% vs. 2.1%, Grade 3: 7.1% vs. 0.2%; p<0.0001), 
breast pain (Grade 1: 31.6% vs. 27.1%, Grade 2: 3.1% vs. 3.4%, p=0.2), 
hematoma (Grade 1: 1.8% vs. 18.8%, Grade 2: 0.8% vs. 0.6%; 
p<0.0001), breast infection (Grade 1: 2.0% vs. 4.5%, Grade 2: 0.2% vs. 
0.5%, Grade 3: 0.2% vs. 0.2%; p=0.09) in the WBI and APBI arm, 
respectively. At 1 year follow-up, significant differences were 
observed between WBI and APBI regarding skin atrophy (Grade 0: 
72.3% vs. 77.8%, Grade 1: 24.0% vs. 21.2%, Grade 2: 3.7% vs. 1.1%; 
p=0.0182) and hyperpigmentation of the skin (Grade 0: 72.7% vs. 
78.5%, Grade 1: 24.4% vs. 20.9%, Grade 2: 3.0% vs. 0.65%; p=0.0126), 
respectively. Regarding other late side-effects as fibrosis, fat 
necrosis, brachial lymphedema, breast pain, teleangiectasia, and 
cosmesis no significant difference was observed between the 
treatment arms at 1-year follow-up.  
Conclusions: Both WBI and APBI are well tolerated and side-effects 
are minimal. One-year late toxicity data suggest that APBI using 
multicatheter BT is associated with significantly less skin related side-
effects compared to WBI. 
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Purpose/Objective: TARGIT-A is an international prospectively 
randomized trial to compare conventional external-beam RT to 'single-
shot' IORT using Intrabeam (Carl Zeiss). The IORT is usually given at 
the same operative procedure and under the same anaesthesia as the 
definitive wide local surgical excision. If unexpected adverse 
pathological features were detected at subsequent pathological 
review, the protocol dictated that EBRT could be added to this group, 
enabling a 'risk-adapted' policy for those with a documented 
additional risk of recurrence, rather than recommending standard 
EBRT for every patient. 
Materials and Methods: Between 2000 and 2012, 3,451 pts with 
unifocal invasive breast carcinoma, aged 45 yrs or over and suitable 
for breast-conserving surgery, were enrolled from 33 centres in 10 
countries. Randomisation could be performed either before the 
surgery (pre-pathology group) or after surgery when the definitive 
pathological review was available (post-pathology group). IORT added 
approx 30-40 min to the procedure. Primary outcome: in-breast 
ipsilateral recurrence (IBR) for all pts, and also assessed separately for 
pre- and post-pathology groups. We specified a 2.5% 'non-inferiority' 
margin for IBR at 5 yrs. Secondary outcome: survival. Exploratory 
analyses: other recurrences incl distant; total death rate; causes of 
death, in particular from breast cancer or other causes. 
Results: The total no. of pts in study was 3451. Patient numbers were 
1721 (TARGIT) and 1730 (EBRT). 1010 pts have a minimum 4 yr follow-
up and 611 have been followed for 5 yrs. Median f/u for the whole 
group = 2.5 yrs. Because of adverse pathological factors, about 15% of 
pts in the IORT group also received EBRT - i.e about 85% did not. This 
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was close to our predicted rate. We documented 34 primary outcome 
events and 117 total events incl IBR, 'all recurrences' (which included 
IBR, loco-regional and/or distant recurrence, and deaths). The 
numbers of events, percentages and confidence intervals were as 
follows, in each case for TARGIT vs EBRT.  IBR events 23 vs 11 ( 3.3% 
vs 1.3%, HR 2.07, CI 1.01 - 4.25 ); 'All recurrences' 69 vs 48 ( 8.2% vs 
5.7%, HR 1.44, CI 0.99-2.08 ); Deaths 37 vs 51 ( 3.9% vs 5.3%, HR 0.7, 
CI 0.46-1.07 ). Thus the IBR event rate was 2.0% higher with TARGIT-
IORT but was within our pre-set non-inferiority margin. In the pre-
pathology group ( approx two-thirds of all pts in study ) the IBR rate 
was 1.0%, and in post-pathology 3.7%. For the secondary outcome 
there was a non-significant trend towards improved overall survival 
for the TARGIT group ( HR 0.7, CI 0.46-1.07), due to fewer non-breast 
cancer deaths (17 vs 35 events, HR 0.47, CI 0.26-0.84). Cardiovascular 
deaths were 2 vs 11 and deaths from other cancers were 7 vs 16. 
Further analyses will be presented at the meeting. 
Conclusions: The risk-adapted approach using TARGIT-IORT resulted 
in a slightly higher IBR rate, though still at present within our pre-set 
'non-inferiority' margin. The pre-pathology group, i.e where the IORT 
was applied immediately after removal of the tumour, had a better 
outcome. The overall death rate was lower in the TARGIT group, due 
to a lower rate of non-breast cancer death.  
 
 SYMPOSIUM: RESEARCH CHALLENGE FROM HORIZON 
2020  
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Horizon 2020 is the financial instrument implementing the Innovation 
Union, a Europe2020 flagship initiative aimed at securing Europe's 
global competitiveness. Running from 2014 to 2020 with an €80 billion 
budget, the EU’s new programme for research and innovation is part 
of the drive to create new growth and jobs in Europe. 
Compared to the previous tools, Horizon 2020 provides a single set of 
rules, combining all research and innovation funding currently 
provided through the 7FP, the innovation related activities of the 
Competitiveness and Innovation Framework Programme (CIP) and the 
European Institute of Innovation and Technology (EIT). 
Simplification in Horizon 2020 (compared to actual 7FP) will target 
three overarching goals: to reduce the administrative costs of the 
participants; to accelerate all processes of proposal and grant 
management and to decrease the financial error rate. 
Mainthree priorities 
Horizon 2020 will focus resources on three distinct, yet mutually 
reinforcing, priorities: 
-  Excellent Science 
This will raise the level of excellence in Europe's science base and 
ensure a steady stream of world-class research to secure Europe's 
long-term competitiveness. It will support the best ideas, develop 
talent within Europe, provide researchers with access to priority 
research infrastructure, and make Europe an attractive location for 
the world's best researchers. 
This will: 
- support the most talented and creative individuals and their teams 
to carry out frontier research of the highest quality by building on the 
success of the European Research Council; 
- fund collaborative research to open up new and promising fields of 
research and innovation through support for Future and Emerging 
Technologies (FET); 
-  provide researchers with excellent training and career development 
opportunities through the Marie Sklodowska-Curie actions15 ('Marie 
Curie actions'); 
- ensure Europe has world-class research infrastructures (including e-
infrastructures) accessible to all researchers in Europe and beyond. 
-  Industrial Leadership 
This will: 
- build leadership in enabling and industrial technologies, with 
dedicated support for ICT, nanotechnologies, advanced materials, 
biotechnology, advanced manufacturing and processing, and space, 
while also providing support for cross-cutting actions to capture the 
accumulated benefits from combining several Key Enabling 
Technologies; 
- facilitate access to risk finance; 
- provide Union wide support for innovationin SMEs. 
- Societal Challenges 
This reflects the policy priorities of the Europe 2020 strategy and 
addresses major concerns shared by citizens in Europe and elsewhere. 
A challenge-based approach will bring together resources and 
knowledge across different fields, technologies and disciplines, 
including social sciences and the humanities. This will cover activities 
from research to market with a new focus on innovation-related 
activities, such as piloting, demonstration, test-beds, and support for 
public procurement and market uptake.It will include establishing 
links with the activities of the European Innovation Partnerships. 
Funding will be focused on the following challenges: 
- Health, demographic change and wellbeing; 
- Food security, sustainable agriculture, marine and maritime 
research and the bio-economy; 
- Secure, clean and efficient energy; 
- Smart, green and integrated transport; 
- Climate action, resource efficiency and raw materials; 
- Inclusive, innovative and secure societies. 
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Modern radiation oncology is a well-established,cost-effective and 
essential component in the curative and palliative treatment of 
malignancy. Indeed, these are exciting times for physicists and 
engineers in Radiotherapy. The challenge of individualized treatment 
optimization continuously drives research and technology, yet we 
should be careful not to get trapped in the “Cargo Cult Science” as 
described by Richard Feynman. In fact that same physicist once 
compared physics to sex by saying: “Sure, it may give some practical 
results, but that’s not why we do it.”  In an attempt of avoiding a 
blind gallop towards increasingly more precise means of tumour 
localization and delivery this physics perspective on research 
challenges will contemplate 3 topics: (a) Due to this cutting edge 
technology, one might argue that radiation oncology, long considered 
to be a physical intervention, is now more accurately conceptualized 
as a biologic intervention with profound effects at the cellular and 
molecular level. The big challenge is to bring these concepts into daily 
clinical routine. To quote yet another physicist, Paul Davis: “It’s like 
trying to run the economy of the US by measuring every transaction in 
every community and city.” (b) As systems become more automated 
and complex the potentials for failure become less intuitively obvious 
and we need more process-oriented rather than device oriented 
Quality Assurance to ensure patient safety. Quoting an ESTRO 
honorary physicist, Pierre Scalliet: “Complex technologies should 
therefore be managed with great foresight, particularly focusing on 
preventive management.” It suffices no longer to prove we can 
irradiate phantoms with high precision, patients demand proof of the 
true delivered dose in their particular case. (c) Scientific and 
technological progress comes at a significant cost,and many concerns 
exist regarding the value of that progress. Within these difficult 
economic times, healthcare politicians face the difficult challenge to 
create a furtive soil (e.g.supporting adequate reimbursement) 
allowing progress through efficacy and driven by outcomes. There is 
also a danger in that too much focus on sophisticated expensive 
technology may create a double layer health care system where not 
all patients have access to the best of care. Ideally, efforts in 
development should also aim at harmonizing the quality of care 
throughout Europe and the rest of the world. 
Technological developments in radiation oncology pave the way for 
tailored individualised therapy within the context of more 
sophisticated and complex treatments. However, the true 
individualised treatment using precise and biological conformal dose 
delivery, requires more than progress in one discipline only and the 
real progress awaits in the synergistic combination of the different 
disciplines allowing upfront identification of the most effective 
treatment for the individual patient and the possible adaptation based 
on response during treatment. This strategy can only work when the 
different treatment platforms evolve simultaneously and allow for 
optimal cross-fertilization. As always, with each step forward we 
realize there is an increased number of things we know too little 
about, or to quote Winston Churchill: “Every day you may make 
progress. Every step may be fruitful. Yet there will stretch out before 
you an ever-lengthening, ever-ascending, ever-improving path. You 
know you will never get to the end of the journey. But this, so far 
from discouraging, only adds to the joy and glory of the climb.”  
 
 
